An innovative research effort has revealed that delivering regenerative cells to developing infants affected by spina bifida during corrective surgery may represent a "major milestone" in treating birth defects.
Trial Details and Safety
The US-based trial involved six developing infants with the 'open' form of spina bifida. Doctors administered regenerative cells sourced from the maternal placenta directly onto the baby's spinal cord as part of the surgical correction.
Importantly, the stem cell application proved to be secure. The study team reported that the therapy did not induce cancerous growths, disrupt the healing process, or prevent the reversal of co-occurring hindbrain herniation.
Positive Developments
Magnetic resonance imaging performed on the newborns indicated a complete reversal of brainstem displacement in every participant. This neurological improvement is strongly associated with enhanced physical outcomes.
"In the event it allows more children capable of walking who otherwise would not, then it would become the conventional approach," noted the study director. "The results are super exciting and open the door to numerous possible new treatments."
Future Implications and Hope
Experts not involved in the trial indicated that subsequent studies of these apparent benefits could signal a "different age" in in-utero treatment. The potential to improve nerve function impairment seen in utero is considered a transformative goal.
Notably important would be improvements in urogenital and gastrointestinal outcomes, which are typical difficulties for those diagnosed with this defect.
Future Directions
Although this preliminary study was small in scale, its established security and encouraging indicators provide a strong foundation for larger, more comprehensive studies. The integration of stem cell therapy with established fetal surgery techniques presents significant potential for changing life trajectories for future generations with spina bifida.